Multicenter, International ALPS Registry Outcomes Just Published in Journal of Endovascular Therapy PARIS – May 19, 2020 — LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease (PAD), today announced publication of positive two-year data from the ALPS [...]

Clinical Study to Evaluate Device’s Ability to Prevent Amputation and Promote Wound Healing in Patients with No Other Options PARIS – December 10, 2019 — LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today that the [...]

PARIS - September 19, 2019 — LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption for the PROMISE II pivotal study of the LimFlow Percutaneous Deep [...]

Dresden Germany 15 December 2014 -- LimFlow today announced that Drs. Andrej Schmidt and Jihad Mustapha will be chairing a session on the LimFlow procedure for treating Critical Limb Ischemia at the upcoming Leipzig Interventional Course or LINC on Tuesday 27 January 2015 starting at 16:00 CET (www.leipzig-interventional-course.com) . Download a schedule of the talks. About [...]

Dresden Germany 30 September, 2014 -- LimFlow today announced that it has closed its Series A financing with a major Family Fund leading the round. The terms and amount were not discussed. About LimFlow GmbH LimFlow is a private, venture-backed medical device company offering a novel therapeutic to treating Critical Limb Ischemia. LimFlow is enrolling [...]